Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Statistics in Medicine
|
June 3, 2017
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study
Jared K Lunceford
Pharmaceutical Statistics
|
April 8, 2015
Clinical utility estimation for assay cutoffs in early phase oncology enrichment trials
Jared K Lunceford
Statistics in Medicine
|
August 13, 2008
Statistical performance of cladistic strategies for haplotype grouping in pharmacogenetics
Jared K Lunceford, Nancy Liu
Statistics in Medicine
|
September 8, 2004
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study
Jared K Lunceford, Marie Davidian
Biometrics
|
March 14, 2002
Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials
Jared K Lunceford, Marie Davidian, Anastasios A Tsiatis
Pharmaceutical Statistics
|
October 14, 2010
Evaluating surrogate variables for improving microarray multiple testing inference
Jared K Lunceford, Guang Chen, Peter H Hu, et al.
Diabetes Care
|
May 9, 2007
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J Goldstein, Mark N Feinglos, Jared K Lunceford, et al.
Diabetes Care
|
November 30, 2006
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner, Mark S Kipnes, Jared K Lunceford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Statistics in Medicine
|
June 3, 2017
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study
Jared K Lunceford
Pharmaceutical Statistics
|
April 8, 2015
Clinical utility estimation for assay cutoffs in early phase oncology enrichment trials
Jared K Lunceford
Statistics in Medicine
|
August 13, 2008
Statistical performance of cladistic strategies for haplotype grouping in pharmacogenetics
Jared K Lunceford, Nancy Liu
Statistics in Medicine
|
September 8, 2004
Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study
Jared K Lunceford, Marie Davidian
Biometrics
|
March 14, 2002
Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials
Jared K Lunceford, Marie Davidian, Anastasios A Tsiatis
Pharmaceutical Statistics
|
October 14, 2010
Evaluating surrogate variables for improving microarray multiple testing inference
Jared K Lunceford, Guang Chen, Peter H Hu, et al.
Diabetes Care
|
May 9, 2007
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J Goldstein, Mark N Feinglos, Jared K Lunceford, et al.
Diabetes Care
|
November 30, 2006
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner, Mark S Kipnes, Jared K Lunceford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Page
of 2